Ashland advances high-growth oral biologics delivery applications with launch of permexa™ sodium caprate to support the scalable development and commercialization of oral peptide, biologic and low-permeability drug products, including rapidly expanding GLP-1 agonists and related therapeutic pipelines.
Ashland advances high-growth oral biologics delivery applications with launch of permexa™ sodium caprate to support the scalable development and commercialization of oral peptide, biologic and low-permeability drug products, including rapidly expanding GLP-1 agonists and related therapeutic pipelines.